LAWRENCE IRWIN GLASS,MICHAEL FREDRICK SNAPE,MICHAEL JOHN BICKERDIKE,PATRICIA PEREZ DE COGRAM
申请号：
BR112015012506
公开号：
BR112015012506A2
申请日:
2013.11.26
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
Summary "Treatment of Autism Spectrum Disorders Using Glycyl-1-2-Methylprolyl-1-Glutamic Acid" This invention provides compounds, compositions and methods for treating autism spectrum disorders (asd) using glycyl-2-methyl-propylyl glutamic acid (g-2-mepe) and analogs thereof. Autism Spectrum Disorders include autism, autistic disorder, asperger's syndrome, childhood disintegrative disorder, invasive developmental disorder - unspecified (pdd-us), fragile x syndrome and rett syndrome. compositions containing the compounds include water-soluble formulations, water-in-oil microemulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets and orally administered gels. The compounds and compositions of this invention may be administered intravenously, intraventricularly, parenterally or orally and may be effective in the treatment of neurodegeneration, promotion of neurological function, treatment of seizure activity and other symptoms of asd and may prolong life in animals, including humans. who have autism spectrum disorders.resumo “tratamento de transtornos do espectro do autismo usando ácido glicil-l-2-metilprolil-l-glutâmico” esta invenção fornece compostos, composições e métodos para tratar transtornos do espectro do autismo (asd) usando ácido glicil-2-metiiprolil-glutâmico (g-2-mepe) e análogos do mesmo. os transtornos do espectro do autismo incluem autismo, transtorno autístico, síndrome de asperger, transtorno desintegrativo da infância, transtorno invasivo do desenvolvimento – sem outra especificação (pdd-nos), síndrome do x frágil e síndrome de rett. as composições contendo os compostos incluem formulações solúveis em água, micro-emulsões água-em-óleo, emulsões grossas água-em-óleo, cristais líquidos água-em-óleo, nanocápsulas, tabletes e géis oralmente administrados. os compostos e composições desta invenção podem ser administrados intravenosamente, intraventricularmente, parenteralmente ou oralmente e podem ser eficazes no trat
